drugset
drugset / Trial / NCT04849299

Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)

NCT04849299 ↗

Phase 1 Completed 24 enrolled Atea Pharmaceuticals, Inc. Hoffmann-La Roche · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will determine the effect of cyclosporine on the PK of AT-527 (R07496998) in healthy male subjects

Timeline

Start
2021-04-18
Primary completion
2021-05-10
Completion
2021-05-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Bemnifosbuvir Other / unclassified 550 mg —
Subject Cyclosporine Peptide 600 mg —

Indications

No indication recorded.